Biologics (Other) CDMOs in Asia-Pacific
28 published
28 published CDMOs match Biologics (Other) in Asia-Pacific.
Locations in this set include United States, China, India, Japan, United Kingdom, and Germany.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, Formulation Development, Quality Control Testing, and Technology Transfer.
Matching companies
Piramal Pharma SolutionsCDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
PortonPorton is a global CDMO offering integrated manufacturing and development services across small molecules, peptides, oligonucleotides, biologics, and conjugates with specialized capabilities in flow chemistry, biocatalysis, and advanced therapies.
ProBioProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Stevanato GroupLeading global provider of integrated drug containment, drug delivery, and diagnostic solutions with 75+ years' experience in glass primary packaging, contract manufacturing, and analytical services across development, clinical, and commercial stages.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Markdown mirror: /modalities/biologics-other/apac.md